Cargando…
An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039447/ https://www.ncbi.nlm.nih.gov/pubmed/27598191 http://dx.doi.org/10.3390/pharmaceutics8030028 |
_version_ | 1782456056961564672 |
---|---|
author | Janagam, Dileep R. Wang, Lizhu Ananthula, Suryatheja Johnson, James R. Lowe, Tao L. |
author_facet | Janagam, Dileep R. Wang, Lizhu Ananthula, Suryatheja Johnson, James R. Lowe, Tao L. |
author_sort | Janagam, Dileep R. |
collection | PubMed |
description | Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release from the ISD systems during the formulation development is laborious and costly. An accelerated release method that can effectively correlate the months to years of long-term release in a short time such as days or weeks is economically needed. However, no such accelerated ISD system release method has been reported in the literature to date. The objective of the current study was to develop a short-term accelerated in vitro release method for contraceptive levonorgestrel (LNG)-containing ISD systems to screen formulations for more than 3-month contraception after a single subcutaneous injection. The LNG-containing ISD formulations were prepared by using biodegradable poly(lactide-co-glycolide) and polylactic acid polymer and solvent mixtures containing N-methyl-2-pyrrolidone and benzyl benzoate or triethyl citrate. Drug release studies were performed under real-time (long-term) conditions (PBS, pH 7.4, 37 °C) and four accelerated (short-term) conditions: (A) PBS, pH 7.4, 50 °C; (B) 25% ethanol in PBS, pH 7.4, 50 °C; (C) 25% ethanol in PBS, 2% Tween 20, pH 7.4, 50 °C; and (D) 25% ethanol in PBS, 2% Tween 20, pH 9, 50 °C. The LNG release profile, including the release mechanism under the accelerated condition D within two weeks, correlated (r(2) ≥ 0.98) well with that under real-time conditions at four months. |
format | Online Article Text |
id | pubmed-5039447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-50394472016-10-04 An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems Janagam, Dileep R. Wang, Lizhu Ananthula, Suryatheja Johnson, James R. Lowe, Tao L. Pharmaceutics Article Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release from the ISD systems during the formulation development is laborious and costly. An accelerated release method that can effectively correlate the months to years of long-term release in a short time such as days or weeks is economically needed. However, no such accelerated ISD system release method has been reported in the literature to date. The objective of the current study was to develop a short-term accelerated in vitro release method for contraceptive levonorgestrel (LNG)-containing ISD systems to screen formulations for more than 3-month contraception after a single subcutaneous injection. The LNG-containing ISD formulations were prepared by using biodegradable poly(lactide-co-glycolide) and polylactic acid polymer and solvent mixtures containing N-methyl-2-pyrrolidone and benzyl benzoate or triethyl citrate. Drug release studies were performed under real-time (long-term) conditions (PBS, pH 7.4, 37 °C) and four accelerated (short-term) conditions: (A) PBS, pH 7.4, 50 °C; (B) 25% ethanol in PBS, pH 7.4, 50 °C; (C) 25% ethanol in PBS, 2% Tween 20, pH 7.4, 50 °C; and (D) 25% ethanol in PBS, 2% Tween 20, pH 9, 50 °C. The LNG release profile, including the release mechanism under the accelerated condition D within two weeks, correlated (r(2) ≥ 0.98) well with that under real-time conditions at four months. MDPI 2016-09-01 /pmc/articles/PMC5039447/ /pubmed/27598191 http://dx.doi.org/10.3390/pharmaceutics8030028 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Janagam, Dileep R. Wang, Lizhu Ananthula, Suryatheja Johnson, James R. Lowe, Tao L. An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems |
title | An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems |
title_full | An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems |
title_fullStr | An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems |
title_full_unstemmed | An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems |
title_short | An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems |
title_sort | accelerated release study to evaluate long-acting contraceptive levonorgestrel-containing in situ forming depot systems |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039447/ https://www.ncbi.nlm.nih.gov/pubmed/27598191 http://dx.doi.org/10.3390/pharmaceutics8030028 |
work_keys_str_mv | AT janagamdileepr anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT wanglizhu anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT ananthulasuryatheja anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT johnsonjamesr anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT lowetaol anacceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT janagamdileepr acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT wanglizhu acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT ananthulasuryatheja acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT johnsonjamesr acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems AT lowetaol acceleratedreleasestudytoevaluatelongactingcontraceptivelevonorgestrelcontaininginsituformingdepotsystems |